Investors Rotate Into Healthcare Stocks, Citing Strong Fundamentals and Attractive Valuations

Investors are shifting capital into U.S. healthcare stocks, betting that a combination of improving earnings, robust dealmaking, and compelling valuations will fuel further gains. The move represents a broadening of the market rally beyond the technology sector, which has dominated returns for much of the year.

Shifting Market Leadership

The S&P 500 healthcare index has climbed 11.2% over the past three months, outpacing the S&P 500's 6% gain to reach a record high, according to market data. This renewed interest is reflected in fund flows, with U.S.-listed healthcare funds attracting $2.44 billion in July, extending a $1.5 billion inflow from June and reversing three prior months of net withdrawals, LSEG Lipper data shows.

Investor sentiment has turned sharply positive. A recent Bank of America survey revealed that global fund managers were a net 32% "overweight" on healthcare stocks in July, a significant jump from 14% in June. Analysts at J.P. Morgan noted that healthcare offers a "rare combination of durable growth, technology-like profitability, attractive valuation and diversification benefits" for investors concentrated in the AI theme.

Fundamentals Underpin Confidence

The sector's appeal is supported by a strong fundamental outlook after it lagged the broader market for the first five months of the year.

Earnings and M&A Activity

Ad

• Earnings Growth: S&P 500 healthcare companies are projected to deliver double-digit earnings growth from the fourth quarter of 2026 through 2027, according to LSEG research. This would mark a significant turnaround from a 16.7% earnings contraction reported in the second quarter of 2026.
• Corporate Performance: Recent results have helped ease concerns, with companies like drugmaker AbbVie and insurer UnitedHealth Group beating profit estimates and raising forecasts.
• Dealmaking: Mergers and acquisitions have also bolstered the sector. M&A value has reached nearly $284 billion this year, approaching the 2025 total of $306 billion, per Dealogic. A recent media report of potential merger talks between AstraZeneca and Bristol-Myers Squibb has further highlighted the trend.

Valuation Appeal

Despite the recent rally, valuations remain a key draw. The healthcare sector is trading at approximately 18 times its 12-month forward earnings expectations. While this is above its 20-year average of 15, it remains below the S&P 500's forward valuation of nearly 20 times. "Healthcare valuations had been depressed for a long time and so there is some opportunity for investors," said Christian Peng, head of healthcare investment banking at Citizens Bank.

Outlook and Political Context

Some market strategists believe this rotation has more staying power than previous attempts. Mark Hackett, chief market strategist for Nationwide, noted that with the S&P 500 at record highs, investors are "actively moving to some of the forgotten areas of the market," which he views as a more sustainable trend.

Analysts also see potential political tailwinds. A divided government following the November midterm elections is viewed by some as a "net positive for the healthcare sector," according to Eric Parnell, chief market strategist at Great Valley Advisor Group, as it could reduce the threat of legislation that might pressure corporate earnings.